Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward
Kiniksa Pharmaceuticals International Plc (Kiniksa) is a biopharmaceutical company that discovers, acquires, develops and commercializes medicines to treat autoinflammatory and autoimmune diseases. The company's pipeline products include rilonacept drug for the treatment of recurrent pericarditis and cardiac sarcoidosis; and KPL-387 targets recurrent pericarditis. Its other products include KPL-1161 and Abiprubart. It develops medicines in the therapeutic areas of cardiovascular, dermatology and autoimmune diseases. The company operates in Switzerland, the US and the UK. Kiniksa is headquartered in London, England, the UK.
Headquarters
United Kingdom
Address
23 Old Bond Street, Floor 3, London, England, WIS4PZ
Website
www.kiniksa.com
No of Employees
366
Industry
Pharmaceuticals and Healthcare
Ticker Symbol & Exchange
KNSA (NASD)
Revenue (2024)
$677.6M
60.1%
(2024 vs 2023)
EPS
XYZ
Net Income (2024)
XYZ
236.6%
(2024 vs 2023)
Market Cap*
$6.3B
Net Profit Margin (2024)
XYZ
185.3%
(2024 vs 2023)
* As of and is in US$
Kiniksa Pharmaceuticals International Plc premium industry data and analytics
Products and Services
| Products | Brands |
|---|---|
| Pipeline | Arcalyst |
| Rilonacept: Recurrent Pericarditis and Cardiac Sarcoidosis | |
| KPL-387: Recurrent Pericarditis | |
| XYZ | |
| XYZ | |
| XYZ |
History
History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.
| Year | Event | Description |
|---|---|---|
| 2025 | New Products/Services | In February, the company announced the development of KPL-387 for recurrent pericarditis, targeting IL-1R1 to inhibit IL-1α and IL-1β signaling. |
| 2025 | Others | In April, the company and Huadong entered into a mutual termination agreement to terminate the mavrilimumab Huadong collaboration agreement. |
| 2022 | Contracts/Agreements | In August, the company entered into a global license agreement with Roche and Genentech for the rights to develop and commercialize vixarelimab, a fully human monoclonal antibody targeting oncostatin M receptor beta (OSMRβ). |
Competitor Comparison
| Key Parameters | Kiniksa Pharmaceuticals International Plc | AbbVie Inc | Novartis AG | Zydus Lifesciences Ltd | Monte Rosa Therapeutics Inc |
|---|---|---|---|---|---|
| Headquarters | United Kingdom | United States of America | Switzerland | India | United States of America |
| City | London | North Chicago | Basel | Ahmedabad | Boston |
| State/Province | England | Illinois | Basel-Stadt | Gujarat | Massachusetts |
| No. of Employees | 366 | 57,000 | 75,267 | 23,283 | 150 |
| Entity Type | Public | Public | Public | Public | Public |
Key Financial Charts
Sales Growth
Net Income Growth
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| Sanj K. Patel | Chairman; Chief Executive Officer | Executive Board | 2015 | 56 |
| Mark Ragosa | Executive Vice President; Chief Financial Officer | Senior Management | 2025 | 51 |
| Ross Moat | Executive Vice President; Chief Operating Officer | Senior Management | 2026 | 45 |
| Michael Megna | Chief Accounting Officer; Senior Vice President | Senior Management | 2025 | 55 |
| Eben Tessari | Chief Strategy Officer; Executive Vice President | Senior Management | 2025 | 44 |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer